CD274 and cancer: In such settings, PD-L1–CAR T cells would eradicate cancer cells, but additionally may also kill the TME cells (such as tumor-associated macrophages), if those were responding to the first CAR-based treatment by upregulating PD-L1 immune checkpoint on their surface.